

**In the Claims:**

1. **(Currently amended)** A composition for organ preservation, comprising an inulin type fructan as an active ingredient **in an amount effective for preservation of the organ, wherein the composition comprises:**

**(a) inulin type fructan 3.5 - 300 g/L;**

**(b) Na<sup>+</sup> 5 - 150 mM;**

**(c) K<sup>+</sup> 5 - 150 mM;**

**and**

**(d) at least one component selected**

**from the group consisting of Cl<sup>-</sup>, HCO<sub>3</sub><sup>-</sup>,**

**CO<sub>3</sub><sup>2-</sup>, organic acids, and organic**

**acid anions 10 - 150 mM.**

2. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is a mixture of two or more inulin type fructans selected from inulin type fructans having a degree of polymerization of 3 to 6.

3. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is 1-kestose.

4. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is nystose.

5. **(Cancelled)** ~~The composition for organ preservation according to claim 1, which comprises:~~

~~(a) inulin type fructan 3.5 - 300 g/L;~~

~~(b) Na<sup>+</sup> 5 - 150 mM;~~

~~(e)  $K^+$  5 - 150 mM;~~

~~and~~

~~(d) at least one component selected~~

~~from the group consisting of  $Cl^-$ ,  $HCO_3^-$ ,~~

~~$CO_3^{2-}$ , organic acids, and organic~~

~~acid anions 10 - 150 mM.~~

6. **(Currently amended)** The composition for organ preservation according to claim **[[5]] 1**, which further comprises at least one of:

(e)  $Mg^{2+}$  0 - 20 mM;

(f)  $Ca^{2+}$  0 - 5 mM;

(g)  $H_2PO_4^-$  and/or  $HPO_4^{2-}$  0 - 150 mM;

and

(h) hydroxyethyl starch 0 - 100 g/L.

7. **(Currently Amended)** The composition for organ preservation according to claim 1, for suppressing or improving hypofunction of and damage to an organ **which possibly occur** during an organ transplantation process.

8. **(Previously presented)** A method for preserving an organ, comprising the step of bringing an effective amount for organ preservation of the composition for organ preservation according to claim 1 into contact with an organ.

9. **(Original)** The method according to claim 8, wherein said contact is carried out by perfusing the organ with the composition for organ preservation.

10. **(Currently Amended)** A method for suppressing or improving hypofunction of and damage to an organ ~~which possibly occur~~ during an organ transplantation process,  
said method comprising the step of bringing an effective amount for suppression or improvement of the composition for organ preservation according to claim 1 into contact with an organ.

11. **(Previously presented)** The method according to claim 8, wherein said organ is selected from the group consisting of kidney, liver, heart, lung, and pancreas.

12. **(Currently amended)** ~~Use of an inulin type fructan for the manufacture of A~~  
method comprising making a composition for organ preservation comprising an  
inulin type fructan as an active ingredient in an amount effective for preservation  
of the organ, wherein the composition comprises:

(a) inulin type fructan 3.5 - 300 g/L;

(b) Na<sup>+</sup> 5 - 150 mM;

(c) K<sup>+</sup> 5 - 150 mM;

and

(d) at least one component selected  
from the group consisting of Cl<sup>-</sup>, HCO<sub>3</sub><sup>-</sup>,  
CO<sub>3</sub><sup>2-</sup>, organic acids, and organic

acid anions 10 - 150 mM.

13. **(Currently Amended)** ~~[[Use]]~~ The method according to claim 12, wherein the inulin type fructan is a mixture of two or more inulin type fructans selected from inulin type fructans having a degree of polymerization of 3 to 6.

14. **(Currently Amended) [[Use]] The method** according to claim 12, wherein the inulin type fructan is 1-kestose.
15. **(Currently Amended) [[Use]] The method** according to claim 12, wherein the inulin type fructan is nystose.
16. **(Currently Amended) [[Use]] The method** according to claim 12, wherein said composition for organ preservation is a perfusate for the organ.
17. **(Currently Amended) [[Use]] The method** according to claim 12, wherein said organ is selected from the group consisting of kidney, liver, heart, lung, and pancreas.